Leveraging Mindsets to Improve Health and Wellbeing in Patients With Cancer

Launched by STANFORD UNIVERSITY · Jul 11, 2019

Keywords

ClinConnect Summary

This clinical trial, titled "Leveraging Mindsets to Improve Health and Wellbeing in Patients With Cancer," is exploring how the way cancer patients think about their condition can impact their health and recovery. Researchers want to understand if changing patients' mindsets—how they view cancer and their treatment—can lead to better physical and emotional health outcomes. The study will follow newly diagnosed patients with specific types of cancer, like breast, lung, or colorectal cancer, from the time they start treatment up to six weeks after. Participants will receive a brief intervention aimed at promoting positive mindsets, and researchers will measure how these mindsets affect their treatment experience and overall well-being.

To be eligible for this study, participants must be 18 years or older, fluent in English, and newly diagnosed with one of the targeted cancers, receiving treatment aimed at curing the disease. They should not have any serious mental health conditions, and previous cancer survivors are not eligible. Throughout the trial, participants can expect to share their thoughts and feelings about their treatment and health, which will help researchers learn more about the connection between mindset and recovery. This study aims to provide valuable insights into how our thoughts can influence our health, especially for those facing a cancer diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • We will only recruit patients ≥ 18 years who are fluent in English and are without cognitive impairment. We have no gender, race, or ethnicity restrictions. Diagnosis of cancer (breast, lung, GI or colorectal, or lymphoma) and treatment given with curative intent.
• • Patients diagnosed with lung cancer, breast cancer, GI/Colorectal cancer, or Lymphoma to be treated with curative intent will be eligible for this study.
• • Participants will be recruited if they are receiving at least one course of systemic treatment. As we are recruiting participants near the point of diagnosis, we will target individuals who have not received prior therapy for cancer.
• • Neither ECOG or Karnofsky Performance Status will be employed
• • Ability to understand and willingness to sign a written informed consent document is required for participation in this study.
• • Treatment plan includes course of systemic treatment involving no less than 4 and no more than 12 infusions.
• Exclusion Criteria:
• • Surgical procedures, if applicable, must take place either before the initiation of systemic treatment or after the last infusion.
• • There are no restrictions regarding the use of other investigational agents; however, use of any investigational agents will be recorded.
• • No active major mental health diagnoses including severe depression, severe anxiety, bipolar / manic depressive disorder, post-traumatic stress disorder, schizophrenia, or any psychotic disorder. Patients with mild depression or anxiety, or depression or anxiety that is well managed with treatment, will not be excluded
• • Pregnant / nursing patients will not be excluded from the study
• • Patients with a previous diagnosis of cancer (cancer survivors) will be excluded from this study. Cancer survivors may already have preconceived notions about the nature of a cancer diagnosis and the course of treatment, and therefore may not respond to our intervention in the same way as individuals who are encountering a cancer diagnosis for the first time.
• • Patients who are HIV-positive will not be excluded.
• • Patients who have major comorbidities that would substantially reduce life expectancy despite successful cancer treatment (i.e., comorbid end stage heart disease or kidney disease) will be excluded from this study.